Method of reducing pulmonary hypertension and atrial fibrillation after surgery using cardiopulmonary bypass
US6011017A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Apr 15, 1998 |
| Grant date | Jan 4, 2000 |
| Priority date | — |
| Expiry date | Apr 15, 2018 |
Classification
- Technology area (CPC H)Electricity
- CPC primaryH04L69/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method is disclosed for using fructose-1,6-diphosphate (FDP) to reduce and prevent two very serious problems caused by surgery that requires cardiopulmonary bypass. Before bypass begins, a liquid that contains FDP is intravenously injected into the patient, preferably over a period such as about 10 to 30 minutes, to allow the FDP to permeate in significant quantity into the heart and lungs while the heart is still beating. FDP can be added to the cardioplegia solution that is pumped through the heart to stop the heartbeat, and/or during bypass. This treatment was found to reduce two very important and serious problems that have unavoidably plagued CPB surgery in the past, which are: (1) elevated levels of pulmonary vascular resistance (PVR), which includes pulmonary hypertension; and (2) high occurrence rates for atrial fibrillation. Prior to this discovery, there has never been any satisfactory treatment which could reduce the severity and occurrence rates for these two major problems. FDP also can be co-administered in this manner, along with (1) a buffering or alkalizing agent that counteracts acidosis, such as sodium bicarbonate or THAM, and/or (2) a drug that reduces the for…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.